Background--Preimplantation balloon aortic valvuloplasty (BAV) is considered a routine procedure during transcatheter aortic valve implantation (TAVI) to facilitate prosthesis implantation and expansion; however, it has been speculated that fewer embolic events and/or less hemodynamic instability may occur if TAVI is performed without preimplantation BAV. The aim of this study was to systematically review the clinical outcomes associated with TAVI undertaken without preimplantation BAV.
T ranscatheter aortic valve implantation (TAVI) is the definitive alternative option for patients with severe symptomatic aortic stenosis that are considered either unsuitable or high risk for surgical aortic valve replacement.
1,2 Preimplantation balloon aortic valvuloplasty (BAV) is a standard procedure during TAVI. Predilation BAV creates fractures of calcified leaflets and increases leaflet flexibility, thereby facilitating delivery of the TAVI catheter across the aortic valve and enhancing prosthesis implantation and expansion within the calcified aortic valve annulus.
Importantly, it has been speculated that fewer embolic events and/or less hemodynamic instability may occur if TAVI is performed without preimplantation BAV. Nonetheless, there is also a concern that omitting preimplantation BAV may result in the need for more postimplant BAV postdilation and possible associated complications. Notably, this approach has been proposed only in single-center studies with relatively small sample sizes; therefore, the benefits of TAVI without preimplantation BAV may be overestimated and subject to significant selection biases. We sought to undertake a systematic review and metaanalysis to study the clinical outcomes associated with TAVI procedures performed with and without preimplantation BAV to gain insight into optimal practice during TAVI procedures.
Methods Eligibility Criteria
We included studies that evaluated patients who underwent TAVI with and without preimplantation (procedural) BAV for predilation. Studies included in the meta-analysis had to be parallel group in design, with one group having TAVI with preimplantation BAV and the other having TAVI without preimplantation BAV. We also included single-arm studies that evaluated the feasibility of performing TAVI without preimplantation BAV. In terms of outcomes, included studies must have evaluated procedural or device success and ≥1 of the following events: need for postimplantation balloon postdilation, valve embolization, need for a second valve, vascular complications, bleeding, neurological events (stroke or transient ischemic attack), acute kidney injury, permanent pacemaker implantation, significant residual aortic regurgitation or paravalvular leakages (PVLs), and mortality. Early safety end point, if available, was reported in accordance to Valve Academic Research Consortium (VARC-2) definitions 3 : all-cause mortality (at 30 days), all stroke (disabling and nondisabling), life-threatening bleeding, acute kidney injury stage 2 or 3 (including renal replacement therapy), coronary artery obstruction requiring intervention, major vascular complication, valve-related dysfunction requiring repeat procedure (BAV, TAVI, or surgical valve replacement). The reporting of outcomes had to include either crude events in each group or any risk or odds estimate (relative risk [RR] , hazard ratio, odds ratio) with a 95% CI. There was no restriction based on the design of the study or the duration of follow-up. We excluded reports in which BAV may have been performed weeks or months before TAVI (so-called bridge-to-TAVI procedure) and isolated case reports, reviews, and editorials.
Search Strategy
We conducted a search of Medline and Embase from conception to September 20, 2015 , using OvidSP (Ovid Technologies).
The following exact search terms were used: ("transcatheter aortic valve implantation" OR "TAVI" OR "transcatheter aortic valve replacement" OR "TAVR") AND ("Balloon aortic valvuloplasty"). There was no restriction based on language of study, and abstracts and unpublished studies were included. The references of the included studies and relevant reviews were checked for additional studies. A flow diagram is provided following the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) (Figure 1 ). Institutional review board approval and patient consent were not required because of the nature of this study as a systematic review and meta-analysis.
Study Selection
Two reviewers (R.B. and C.S.K.) independently checked all titles and abstracts for studies that met the inclusion criteria. The full reports of potentially relevant studies were retrieved, and data were independently extracted on study design, participant characteristics, treatment groups, outcome events, follow-up, and results. Any discrepancies between reviewers were resolved by consensus after consulting a third reviewer (M.A.M.). 
Quality Assessment
Risk of bias was assessed by considering ascertainment of treatment groups, ascertainment of outcomes, loss to followup, and consideration of potential confounders in the data analysis. Publication bias was assessed using funnel plots if there were >10 studies in a meta-analysis and no evidence of substantial statistical heterogeneity. 4 
Data Analysis
We used RevMan (version 5.1.7; Nordic Cochrane Centre) to perform random-effects meta-analysis using the Mantel-Haenszel method to determine pooled risk ratios for dichotomous data. The I 2 statistic was used to assess the consistency among studies, with I 2 <25% considered low, I 2 =50% considered moderate, and I 2 >75% considered high heterogeneity. If data or studies for meta-analysis were insufficient, we pooled the studies using a weighted average or performed a narrative synthesis of studies that were too heterogeneous to pool. Sensitivity analyses were further performed according to the access site and type of valve for meta-analysis.
Results

Study Population
A total of 16 studies [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] including 1395 patients fulfilled the inclusion criteria ( Figure 1 ). The sample size, age, sex, hemodynamic echocardiographic data, predicted operative mortality risk evaluation scores, and some of the baseline characteristics are described in Table 1 . Among the studied populations, TAVI was performed without preimplantation BAV in 721 patients and with preimplantation BAV in 674 patients. The mean age was 81.3 years, and 49.6% of participants were female in 14 studies that reported both age and sex. [5] [6] [7] [8] [9] 11, [14] [15] [16] [17] [18] [19] [20] The balloon-expandable Edwards SAPIEN XT or SAPIEN 3 valve was implanted in 10 studies 6, [10] [11] [12] 14, [16] [17] [18] [19] [20] including 793 patients, and the self-expandable Medtronic CoreValve was used in 7 propensity-matched study. 16 
Study Designs and Quality Assessment
Study design, time frame, country of origin, and quality assessment for included studies are reported in Table 2 . Ascertainment of outcomes varied from medical record reviews to prospective evaluation with adjudicated clinical end points. All studies contained reliable data, and there was no loss to follow-up. Follow-up of patients varied and included in-hospital outcomes, clinical visits, echocardiographic 
Association of Preimplantation BAV Versus No BAV and Outcomes
Device type, access site, procedure-related outcomes, and follow-up assessment for all included studies reporting crude rate of events are summarized in Table 3 . A pooled analysis reporting crude rates for outcomes of studies with and without preimplantation BAV according to valve type is shown in Table 4 . Further separate analyses were performed including only studies of patients undergoing TAVI without preimplantation BAV (Table 5 ) and with preimplantation BAV (Table 6 ).
In-Hospital and 30-Day Outcomes
Crude device success rate was reported in all studies [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] and achieved in 94% (1311 of 1395) of patients without differences between valve types. Crude all-cause mortality at 30 days was reported in 15 studies [5] [6] [7] [8] [9] [10] [11] [13] [14] [15] [16] [17] [18] [19] [20] and occurred in 6% (72 of 1282) of patients. The safety composite end point was reported in 6 studies 7, 9, 11, 12, 18, 19 and occurred in 21% (111 of 537) of patients. The crude incidence of residual moderate or severe aortic regurgitation or PVL was reported in 9 studies 5-9,12-14 and occurred in 16% (124 of 757) of patients. In this regard, 4 studies used the balloon-expandable valve 6, 12, 14, 20 with a 3% rate (9 of 262 patients), and 5 studies used the self-expandable valve 5,7-9,13 with a 23% rate (115 of 495 patients). Of note, the need for postimplantation postdilation was reported in 
Sensitivity Analysis
We conducted a sensitivity analysis for clinical outcomes with and without preimplantation BAV according to the different access sites, comparing the transfemoral with transapical and transfemoral or any other access including the direct aortic and trans-subclavian routes (Table 7 , Figures 2 through 4) . Those who underwent TAVI without preimplantation BAV and with the transfemoral or any other access were marginally associated with more cardiac tamponade (RR 3.61, 95% CI 1.04-12.56, P=0.04). Studies including the transfemoral access only were associated with higher mortality among patients who underwent TAVI with preimplantation BAV (RR 0.30, 95% CI 0.11-0.82, P=0.02); however, this difference disappeared when analyzed as a whole access-site sample (RR 0.61, 95% CI 0.32-1.14, P=0.12).
We also performed sensitivity analysis according to valve type (Table 8 , Figures 5 through 7) . The self-expandable valve tended to be associated with more cardiac tamponade (RR 3.64, 95% CI 0.94-14.14, P=0.06) when the procedure was No significant differences were found between the different access sites and valve types among the remaining analyzed variables. Importantly, neither the access site nor the valve type affected device success rate, safety composite end point, or mortality (Tables 7 and 8 ).
Discussion
The results of this meta-analysis show no significant differences between patients undergoing TAVI either with or without preimplantation BAV with respect to mortality, neurological events, permanent pacemaker implantation, or improvement in device success (including repeat procedure, significant residual PVL or aortic regurgitation, and the need for postimplantation postdilation).
Rationale and Adjunctive Utilities of Preimplantation BAV During TAVI
The pathophysiology of aortic stenosis and calcification make it reasonable to hypothesize that crossing the heavily calcified valve by the transapical antegrade approach would not require predilation. 6, 11, 16, 19 In contrast, in transfemoral or other retrograde procedures, preimplantation BAV remains important to ensure smooth crossing of the TAVI delivery system. Notably, our results show more cardiac tamponade without BAV, although one may be cautious in interpreting results based on only 2 studies. 13, 14 Forceful pushing of the device and movement of the stiff wire inside the ventricle might cause this issue. Importantly, even if the valve is successfully crossed with the TAVI system, failure to fully expand the transcatheter valve may translate into hemodynamic instability due to leaflet incompetence, significant PVL, valve migration, or further need for postdilation with inherent risk of valve migration. 5, 9, 21 In fact, some studies reported the need for bailout BAV predilation when TAVI was initially planned without preimplantation BAV. [7] [8] [9] 21 Moreover, a partial balloon-tip inflation technique was reported to facilitate crossing of the aortic valve. 10, 12 Coronary ostia <10 to 11 mm from the aortic annulus represent a hazard for coronary obstruction, 22, 23 especially in narrow, tubular, or porcelain aortic roots exhibiting longitudinal remodeling. 22, 24 In these cases, simultaneous aortogram at the time of BAV is helpful to assess the behavior of the heavily calcified aortic leaflets, especially the left leaflet toward the left main coronary artery. 9, 22 Finally, performing preimplantation BAV also allows confirmation of reliable pacing-wire capture. In the case of capture failure, albeit rare, it is preferable to deal with this issue during BAV rather than during balloon-expandable valve deployment.
Residual Aortic Regurgitation and PVL
It is well known that the incidence of PVL is associated with worse short-and long-term outcomes. [25] [26] [27] Our results show a higher pooled incidence of PVL with the self-expanding valve compared with the balloon-expandable valve, and these percentages remained much higher even if analyzing groups with and without preimplantation BAV separately. Indeed, these results are in line with previously reported evidence. 27, 28 Interestingly, Fiorina and colleagues 9 reported lower incidence of moderate to severe PVL without preimplantation BAV; however, hemodynamics were not statistically different between the 2 strategies, as assessed by aortic regurgitation index, likely due to low incidence of severe PVL. It is quite provocative to suggest that performing TAVI without preimplantation BAV may reduce PVL, mostly using the self-expandable valve because of its delivery mechanism, composed of a self-expanding nitinol frame. Regarding the balloon-expandable bioprosthesis, PVL reduction might have been related to better understanding of valve sizing (and slight oversizing) that progressed along the same learning curve and led to confidence in direct implantation. In addition, some studies included the SAPIEN 3 bioprosthesis, which includes a specific anti-PVL sealing design.
Need for Postimplantation Postdilation
According to our results, the self-expanding valve was associated with a crude 2-fold greater need for postdilation. Importantly, postimplantation postdilation can also cause device migration and thus increase PVL 9 as well as the risk for annular rupture with postdilation than with predilation. Although avoiding BAV minimizes manipulation of the severely calcified aortic annulus or native valve, it must be balanced with the potential need for more postdilation to correct a significant residual PVL. Furthermore, the impact of postdilation on the long-term valve outcome remains unknown.
Aortic Valve Calcification Assessment to Plan TAVI Without Preimplantation BAV
The degree and distribution of aortic valve calcification and annular morphology has been correlated with postprocedural PVL. [29] [30] [31] [32] Moreover, the location and/or asymmetry of this calcification, more often located at the noncoronary cusp and/or device landing zone, is more important than the total calcium load. 20, 29, 31 Interestingly, Mollmann and colleagues 14 showed no differences in the extent of valve calcification, as assessed by Agatston score, among patients treated with the 2 strategies. In addition, they found no correlation between the aortic valve area and load of calcification with the duration of the procedure, fluoroscopy time, radiation dose, or contrast amount. Similarly, Fiorina et al 9 found no correlation between residual PVL and the degree of calcification in the device landing zone among those who received TAVI without preimplantation BAV. Of note, the authors also reported that among patients who received preimplantation BAV, bigger prosthesis size indicated higher incidence of significant PVL, although that relationship was not observed in patients in which TAVI was undertaken without preimplantation BAV. 
Neurological Events
It has been hypothesized that TAVI without preimplantation BAV may be associated with fewer embolic events, especially fewer cerebrovascular accidents. Strikingly, relatively low stroke rates have been reported with the 2 strategies and the 2 TAVI devices. The different technique by which the balloonexpandable valve is deployed, more often oversized, compared with the self-expandable valve (less aggressive expansion technique) may explain the higher potential for calcific embolization. In this regard, the new-generation balloonexpandable Edwards SAPIEN 3 valve requires less overexpansion compared with the SAPIEN XT; however, most of the analyzed studies failed to support avoiding a preimplantation BAV strategy with reduced neurological complications. Moreover, Aggarwal and colleagues 12 reported no differences between groups in terms of embolic load based on transcranial Doppler, including number in solid, gaseous, or total emboli (P>0.05 for all). In addition, Bijuklic et al 20 showed no difference in terms of silent embolic events assessed by diffusion-weighted cerebral magnetic resonance. Interestingly, a large volume was observed among those undergoing TAVI without preimplantation BAV. Importantly, the authors reported that 4 patients experienced stroke, 3 of them without preimplantation BAV and 1 patient with preimplantation BAV. Nonetheless, because of the exclusion criteria stated in the methodology, these patients were excluded from analysis because of a clinically apparent stroke within 3 days after TAVI. 20 
Potential Benefits of TAVI Without Preimplantation BAV
Preimplantation BAV might be poorly tolerated by certain patients. The time between BAV predilation and TAVI is a particularly crucial period, especially in patients with preexisting severe left ventricular systolic dysfunction and/or pulmonary hypertension. Moreover, the temporary interruption in ventricular output during rapid ventricular pacing and BAV outflow occlusion itself can result in hemodynamic compromise. Furthermore, significant aortic regurgitation following BAV can precipitate clinically important instability, even in patients with normal left ventricular function; this hemodynamic deterioration can be sudden, profound, and not entirely predictable. The special subset of patients presenting with and/ or prone to hemodynamic instability can experience multiorgan hypoperfusion, mainly cerebral and renal; therefore, avoiding a rapid pacing run for BAV may prevent an unnecessary period of hypotension in certain cases. Alternatively, it is logical that performing TAVI without preimplantation BAV is associated with a reduction in contrast volume, 6, 11, 14, 18, 20 fluoroscopy time, 12, 16, 18 radiation dose, 14 or total procedural time. 6, 17, 20 The clinical impact of these differences is uncertain.
Limitations
The present study has several limitations. The main limitation lies with the small number of patients within each study and the nonrandomized nature of the included studies that may introduce selection bias. Importantly, the decision of whether or not to predilate was made at the discretion of the TAVI team operator and may relate to the complexity of the valve anatomy and the operator's perception of successful valve delivery; therefore, it is possible that BAV was undertaken in more complex and challenging cases, subjecting comparison of outcomes to selection bias. In addition, patient-level data were not available for this analysis, precluding more robust adjustment for any differences in clinical or anatomical variables. Nevertheless, in studies that reported clinical demographics and anatomical features of the patients, these variables were relatively well matched in both BAV/non-BAV studied cohorts. Notably, many of the studies included in this analysis lacked data on whether patients had hemodynamic compromise and/ or poor left ventricle function necessitating BAV prior to the index TAVI procedure (bridge to TAVI). Finally, patients exhibiting major comorbidities and clinically uncertain benefit from TAVI may have been offered BAV as a potential bridge or palliation due to an adverse profile, with subsequent definitive treatment (TAVI) offered after substantial improvement. 
Conclusion
Our analysis suggests that TAVI procedures with or without preimplantation BAV were associated with similar outcomes for a number of clinically relevant end points. Further studies including large number of patients are needed to ascertain the impact of TAVI without preimplantation BAV as a standard practice. Meanwhile, our findings provide real-world data that may contribute to the current practice of TAVI operators and influence future perspectives. Notably, a simplified procedure can be safely performed and achieve comparable results.
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